Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18 Ovarian Neoplasms 8 Neoplasms 7 Colorectal Neoplasms 5 Recurrence 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Glioblastoma 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Radiation Pneumonitis 2 Peritoneal Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Fallopian Tube Neoplasms 2 Carcinoma, Renal Cell 2 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasm Metastasis 1

Interventions

pembrolizumab 157 Gemcitabine 140 Capecitabine 123 Paclitaxel 121 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Docetaxel 98 Leucovorin 97 Cisplatin 90 Radiosurgery 88 Irinotecan 88 Carboplatin 86 Cyclophosphamide 72 Cetuximab 72 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × nintedanib × Clear all

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡